- Details
- In this UroToday presentation Christopher Wallis and Zachary Klaassen, continue their discussion on the NCCN prostate cancer clinical practice guidelines in oncology focusing on observation and Active Surveillance (AS). The AS section of the NCCN Guidelines includes an introduction, the rationale, patient selection, confirmatory testing by discussion of an Active Surveillance program, as well as r...
|
- Details
- Christopher Wallis and Zachary Klaassen, continue their discussion on the NCCN clinical practice guidelines in oncology focusing on prostate cancer and the recently released and published update of these guidelines from September 2021. In this conversation the pair focus on questions relating to the initial clinical assessments, staging evaluation, and imaging approaches in prostate cancer. Biogra...
|
- Details
- The UroToday Journal Club presentation from Christopher Wallis and Zachary Klaassen discuss the NCCN clinical practice guidelines in oncology focusing on prostate cancer genetics. To set the stage for discussing prostate cancer genetics, they start with a background on genetics and then focus on three specific aspects of prostate cancer genetics, namely homologous recombination repair, DNA mismatc...
|
- Details
- In this UroToday Journal Club presentation from Christopher Wallis and Zachary Klaassen, the pair continue their discussion on the NCCN clinical practice guidelines in oncology, with a focus on prostate cancer. This discussion is part two of a two-part series focusing on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer. For patients with metastatic castration-resistant...
|
- Details
- In this UroToday Journal Club presentation from Christopher Wallis and Zachary Klaassen, the pair continue their discussion on the NCCN clinical practice guidelines in oncology, with a focus on prostate cancer. This discussion is part one of a two-part series focusing on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer. For patients with metastatic castration-resistant...
|
- Details
- Christopher Wallis and Zachary Klaassen review the NCCN clinical practice guidelines on prostate cancer. This discussion is the third part of their discussion of androgen deprivation therapy (ADT). Dr. Wallis begins this discussion with a conversation on intermittent vs continuous ADT for patients with prostate cancer. He examines the quality of life in conjunction with survival measurements. Abou...
|
- Details
- In this UroToday discussion between Zachary Klaassen and Christopher Wallis, the pair discuss the NCCN clinical practice guidelines in oncology, specifically looking at prostate cancer. This part of the conversation specifically looks at androgen deprivation therapy (ADT) for castration-naive disease. Dr. Klaassen begins by discussing the different categories that ADT has been categorized into rec...
|
- Details
- Zachary Klaassen and Christopher Wallis discuss the NCCN guidelines for castration-resistant prostate cancer (CRPC) updated in February of 2021. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta U...
|
- Details
- UroToday is introducing an in-depth look at the NCCN Guidelines on Prostate Cancer. In this video presentation, Zachary Klaassen and Christopher Wallis focus on Androgen Deprivation Therapy (ADT), which is broken down into six subsections including ADT for clinically localized N0M0 disease, ADT for regional disease, palliative ADT, ADT for castration-naive disease, intermittent versus continuous A...
|